Les interactions CBD / médicaments Posté le 6 avril 2020 par Swiss Medical Cannabis Depuis l’augmentation de sa demande, le cannabidiol (CBD) attire significativement l’attention sur son potentiel à soulager les symptômes de l’insomnie, de l’anxiété, de la douleur chronique et d’une foule d’autres problèmes de santé. Les recherches menées à ce jour démontrent progressivement que le CBD est d’une grande sécurité d’emploi même à forte dose et peu d’effets secondaires, somme toute mineurs. Toutefois, il existe une mise en garde : le CBD peut interagir avec certains médicaments. L’interrogation porte ainsi sur la façon dont le corps métabolise certaines substances. Avant de [...]
Lire la suiteThe Impact of Cannabidiol on Psychiatric and Medical Conditions Thersilla Oberbarnscheidt, Norman S. Miller Journal of Clinical and Medical Research, 2020, 12, (7), 393-403. Doi : 10.14740/jocmr4159 Abstract Cannabidiol (CBD) is a substance chemically derived from Cannabis sativa and discussed to be non-psychoactive. According to the FDA, marijuana is classified as a schedule I substance; however, hemp which is defined as extracts from marijuana including cannabinoids containing less than 0.3% tetrahydrocannabinol (THC), is excluded from that controlled substance act and available at local convenience stores in the US as it is seen as an herbal supplement. CBD is purported to be used for various medical [...]
Lire la suiteCannabis for Migraine Strongly Linked to Rebound Headache, Megan Brooks, Medscape Medical News, 2021
Cannabis for Migraine Strongly Linked to Rebound Headache Megan Brooks Medscape Medical News © March 09, 2021 Patients with chronic migraine who turn to cannabis to relieve headache pain may be setting themselves up for medication overuse headache, preliminary research suggests, although the direction of the relationship is unclear. Researchers at Stanford University School of Medicine, Stanford, California, found a significant increase in the likelihood of medication overuse headache (rebound headache) in chronic migraine patients who use cannabis. Dr Niushen Zhang "This study shows that there is some kind of association between cannabis use and medication overuse headache in people with chronic migraine," lead investigator Niushen Zhang, MD, [...]
Lire la suiteMedical Cannabis Use Rising Among Older Adults Pauline Anderson Medscape Medical News ©March 22, 2021 More individuals are using medical cannabis, but the increase appears to be more pronounced among seniors, new research suggests. Results of a large Canadian survey study show that the proportion of older users among total users increased from 17.6% before 2017 to 26.7% in 2018 and 31.2% in 2019. The proportion of older users was 22.7% in 2020, but there were fewer participants in this latest sample (8869 in 2019 and 5644 in 2020). The majority of older respondents reported that they use cannabis to relieve pain and prefer cannabidiol [...]
Lire la suiteCannabidiol as an Intervention for Addictive Behaviors : A Systematic Review of the Evidence Mélissa Prud’homme, Romulus Cata and Didier Jutras-Aswad Substance Abuse : Research and Treatment, 2015, 9, 33-38. doi : 10.4137/SART.S25081. Abstract : Drug addiction is a chronically relapsing disorder characterized by the compulsive desire to use drugs and a loss of control over consumption. Cannabidiol (CBD), the second most abundant component of cannabis, is thought to modulate various neuronal circuits involved in drug addiction. The goal of this systematic review is to summarize the available preclinical and clinical data on the impact of CBD on addictive behaviors. MEDLINE and PubMed were searched [...]
Lire la suiteCannabis for Pain? An Expert's Guidance John Watson Medscape Neurology © 2021 WebMD, LLC January 05, 2021 Mark Steven Wallace, MD Many have put forth medical cannabis as a promising treatment for chronic pain that can potentially replace opioids. However, although it's never been easier for patients to access medical cannabis, those researching its use say that the structural challenges inherent to studying a Schedule 1 drug remain formidable. Medscape recently spoke with Mark Steven Wallace, MD, a pain management specialist and chair of the Division of Pain Medicine at UC San Diego Health, about the latest data on medical cannabis and the challenges in studying its clinical use in pain [...]
Lire la suiteNeuroprotection Following Concussion : The Potential Role for Cannabidiol Jyotpal Singh, John Patrick Neary Canadian Journal of Neurological Sciences, 2020, 1–12 doi : 10.1017/cjn.2020.23 ABSTRACT : Cannabidiol (CBD) has been generating increasing interest in medicine due to its therapeutic properties and an apparent lack of negative side effects. Research has suggested that high dosages of CBD can be taken acutely and chronically with little to no risk. This review focuses on the neuroprotective effects of a CBD, with an emphasis on its implications for recovering from a mild traumatic brain injury (TBI) or concussion. CBD has been shown to influence the endocannabinoid system, both by [...]
Lire la suiteAdd-On Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex. A Placebo-Controlled Randomized Clinical Trial Elizabeth A. Thiele, MD, PhD; E. Martina Bebin, MD, MPA; Hari Bhathal, MD; Floor E. Jansen, MD; Katarzyna Kotulska, MD, PhD; John A. Lawson, BMed, PhD; Finbar J. O'Callaghan, MBChB, PhD; MichaelWong,MD, PhD; Farhad Sahebkar, MD; Daniel Checketts, MSc; Volker Knappertz, MD; for the GWPCARE6 Study Group JAMA Neurology, 2020, December 21 online, E1-E7. doi : 10.1001/jamaneurol.2020.4607 IMPORTANCE : Efficacy of cannabidiol has been demonstrated in seizures associated with Lennox-Gastaut and Dravet syndromes but appears not yet to have been established in conditions with primarily focal seizures, such as [...]
Lire la suiteCannabis and Cannabinoids: Weighing the Benefits and Risks in Psychiatric Patients Diana M. Martinez, MD Medscape .com, December 18, 2020 This transcript has been edited for clarity. Hello. I'm Diana Martinez. I'm a psychiatrist at the Columbia University Medical Center in the Department of Psychiatry. Today we'll be talking about the interaction between cannabis and psychiatric disorders. When I say "cannabis," this is really the same as marijuana. I use the term "cannabis" because this is a scientific term for the plant. I'm going to start with a brief history of cannabis. It’s been used for centuries in India as both an intoxicant and a [...]
Lire la suiteNouvelle classification du cannabis : le service minimum de la Commission des stupéfiants de l’ONU par L630 | Déc 2, 2020 | Communiqué https://l630.org/nouvelle-classification-du-cannabis-le-service-minimum-de-la-commission-des-stupefiants-de-lonu/ Ce 12 décembre, la Commission des stupéfiants des Nations-Unies a décidé de modifier la classification du cannabis au sein des conventions internationales. Le cannabis n’est plus classé comme un stupéfiant du tableau IV, c’est-à-dire ayant un potentiel d’abus fort et des effets nocifs importants, sans valeur thérapeutique notable. L630 réagit. COMMUNIQUE DE PRESSE. L630 se félicite de la décision de la Commission des Stupéfiants des Nations-Unies de retirer le cannabis du tableau des stupéfiants sans intérêt médical. Cette décision [...]
Lire la suite